ZYNE Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals Inc together with its subsidiary is a pharmaceutical company which is focused on developing and commercializing proprietary next generation synthetic cannabinoid therapeutics formulated for transdermal delivery.

$4.28
As of 04/09/2021     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—Specialty &
Index country:  USA
Country of incorporation:  USA
IPO date:  08/05/2015
Outstanding shares:  41,251,537
Average volume:  1,956,139
Market cap:   $176,556,578
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    98986X109
ISIN:        US98986X1090
Sedol:      BZ03R68

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   2.12
PS ratio:   0.00
Return on equity:   -85.36%
Net income %:   0.00%